Livedo aPL Significance — SCE Rheumatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — An aPL-associated non-criteria vasculopathy; assess thrombotic risk and consider aspirin
The persistent, irregular pattern is livedo racemosa, an aPL-associated, non-criteria cutaneous small-vessel manifestation rather than physiological cold-induced livedo. It should prompt assessment of the full thrombotic risk profile and control of modifiable cardiovascular and venous-thromboembolism risks. This patient has a high-risk aPL profile because lupus anticoagulant and high-titre anticardiolipin antibodies are persistently present. EULAR recommends considering low-dose aspirin, usually 75–100 mg daily, in SLE without previous thrombosis but with a high-risk aPL profile, after considering bleeding risk. Livedo alone does not establish thrombotic APS or Sneddon syndrome; Sneddon syndrome requires associated cerebrovascular disease. There is no evidence here of inflammatory cutaneous vasculitis or other organ-threatening lupus warranting high-dose glucocorticoids or cyclophosphamide, and therapeutic anticoagulation is not indicated without a thrombotic event.
Reference: EULAR, Fanouriakis A et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update, recommendation 12, published online 12 October 2023. https://www.eular.org/document/download/724/fe9e2ce7-b682-4f2f-aa41-7983eeb7a05c/697